IFNγ score-based neoadjuvant immunotherapy for stage III melanoma.
Keitaro FukudaPublished in: The Journal of experimental medicine (2023)
In this issue of JEM, Reijers et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.